Israel - English - Ministry of Health

mbi pharma ltd., israel - cytarabine - solution for infusion - cytarabine 4000 mg / 80 ml - cytarabine - ara-cell® 4000 mg is indicated for induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas (non-hodgkin's lymphomas of high malignancy).

Israel - English - Ministry of Health

mbi pharma ltd., israel - cytarabine - concentrate for solution for infusion - cytarabine 5 g / 50 ml - cytarabine - ara-cell® 100 mg/ml is used in combination with other cytostatic agents in high-dose therapy for:• refractory non-hodgkin’s lymphoma• refractory acute non-lymphocytic leukaemia• refractory acute lymphoblastic leukaemia• recurrent cases of acute leukaemia• types of leukaemia with special risk: – secondary leukaemia following previous chemotherapy and/or radiation treatment – manifest leukaemia following transformation of pre-leukaemia• consolidation of the remission of acute non-lymphocytic leukaemia in patients under 60 years of age.

Israel - English - Ministry of Health

mbi pharma ltd., israel - cytarabine - concentrate for solution for infusion - cytarabine 5 g / 50 ml - cytarabine - ara-cell® 100 mg/ml is used in combination with other cytostatic agents in high-dose therapy for:• refractory non-hodgkin’s lymphoma• refractory acute non-lymphocytic leukaemia• refractory acute lymphoblastic leukaemia• recurrent cases of acute leukaemia• types of leukaemia with special risk: – secondary leukaemia following previous chemotherapy and/or radiation treatment – manifest leukaemia following transformation of pre-leukaemia• consolidation of the remission of acute non-lymphocytic leukaemia in patients under 60 years of age.

Israel - English - Ministry of Health

mbi pharma ltd., israel - mesna - solution for injection - mesna 100 mg / 1 ml - mesna - prevention of urinary tract toxicity of oxazaphosphorines (the active components of ifosfamide, cyclophosphamide , trofosfamide) in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous ifosfamide, cyclophosphamide or trofosfamide, urinary passage diseases in anamnesis.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - lisinopril -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn bhd - lisinopril -

Philippines - English - FDA (Food And Drug Administration)

for: stadapharm gmbh; importer: croma medic, inc.; distributor: croma medic, inc. - bicalutamide - film-coated tablet - 50mg